Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Real world evaluation of three models of NHS smoking cessation service in England.

Mardle T, Merrett S, Wright J, Percival F, Lockhart I.

BMC Res Notes. 2012 Jan 6;5:9. doi: 10.1186/1756-0500-5-9.

2.

'Real-world' effectiveness of smoking cessation treatments: a population study.

Kotz D, Brown J, West R.

Addiction. 2014 Mar;109(3):491-9. doi: 10.1111/add.12429. Epub 2013 Dec 20.

PMID:
24372901
3.

Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.

Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S.

Clin Drug Investig. 2009;29(10):655-65. doi: 10.2165/11317730-000000000-00000.

PMID:
19715382
5.

A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.

Xenakis JG, Kinter ET, Ishak KJ, Ward AJ, Marton JP, Willke RJ, Davies S, Caro JJ.

Pharmacoeconomics. 2011 Jun;29(6):497-510. doi: 10.2165/11589230-000000000-00000.

PMID:
21452908
6.

Comparison of the effectiveness of varenicline and combination nicotine replacement therapy for smoking cessation in clinical practice.

Brose LS, West R, Stapleton JA.

Mayo Clin Proc. 2013 Mar;88(3):226-33. doi: 10.1016/j.mayocp.2012.11.013. Epub 2013 Feb 27.

PMID:
23489449
7.

Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews.

Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T.

Addiction. 2014 Sep;109(9):1414-25. doi: 10.1111/add.12633. Epub 2014 Jul 4. Review.

PMID:
24995905
8.

Varenicline in the management of smoking cessation: a single technology appraisal.

Hind D, Tappenden P, Peters J, Kenjegalieva K.

Health Technol Assess. 2009 Sep;13 Suppl 2:9-13. doi: 10.3310/hta13suppl2/02. Review.

9.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
10.
11.

General practitioner prescribing of single and combination nicotine replacement therapy in the UK: a retrospective database study.

Johnson M, Anderson P, Lockhart I.

BMC Fam Pract. 2014 Mar 20;15:47. doi: 10.1186/1471-2296-15-47.

12.

Tobacco quitline outcomes by service type.

Kerkvliet JL, Fahrenwald NL.

S D Med. 2014 Jan;67(1):25-9.

PMID:
24601063
13.

Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.

Lutz MA, Lovato P, Cuesta G.

Hosp Pract (1995). 2012 Feb;40(1):35-43. doi: 10.3810/hp.2012.02.946.

PMID:
22406881
14.
15.

Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.

Athanasakis K, Igoumenidis M, Karampli E, Vitsou E, Sykara G, Kyriopoulos J.

Clin Ther. 2012 Aug;34(8):1803-14. doi: 10.1016/j.clinthera.2012.07.002. Epub 2012 Jul 20.

PMID:
22818870
16.

Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.

Keating GM, Lyseng-Williamson KA.

Pharmacoeconomics. 2010;28(3):231-54. doi: 10.2165/11204380-000000000-00000. Review.

PMID:
20108995
17.

Smoking cessation interventions: a primer for physicians: Comment on "Use of varenicline for 4 weeks before quitting smoking".

Simon JA.

Arch Intern Med. 2011 Apr 25;171(8):777-8. doi: 10.1001/archinternmed.2011.137. No abstract available.

PMID:
21518947
18.

[Results of a multidisciplinary program to quit smoking].

Peña P, Zagolin M, Acuña M, Navarrete S, Bustamante P, Suárez C, Cavada G, Bertoglia MP.

Rev Med Chil. 2013 Mar;141(3):345-52. doi: 10.4067/S0034-98872013000300010. Spanish.

19.

Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.

Lutz MA, Lovato P, Cuesta G.

Hosp Pract (1995). 2012 Feb;40(1):24-34. doi: 10.3810/hp.2012.02.945.

PMID:
22406880
20.

Supplemental Content

Support Center